Novel micro-RNA therapeutic hits early targets in ischemic heart diseases
Earlier this year, Horizon announced a new collaboration and license agreement with Mammoth Biosciences.
Read More
Tag: RNA oligonucleotides
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
